Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With Neoadjuvant Gem-iDRS ± Cetrelimab in MIBC
A biomarker analysis of SunRISe-4 found that high baseline TMB, GBD, and PD-L1 expression were associated with pathologic overall response to the regimen.
source
Reporting by onclive. The original article may no longer be reachable at its published URL.
read at onclive ↗
comments(0)
5-min edit window · permanent after that